Möchten Sie immer auf dem neuesten Stand bleiben?

In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading...

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE...

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and...

Events plan to highlight BolaWrap®, WrapReality™, and WRAP’s integrated approach to tools, training, and policy for modern public safety in European market

Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in...

INVIAH is an AI-powered physician home-visit platform that brings in-person medical care for urgent and elective needs directly to patients’ homes.

Tampa, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- The Board of Trustees of Vocate Education Solutions, Inc. (Vocate) today announced the appointment of Alexandra Schaffrath as President and Chief...

FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and...

SONATA-HCM anticipated to be fully enrolled mid-2026  Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851...